Roche taps Simcere for autoimmune trispecific for $1.53bn
Article from Pharmaphorum about Roche taps Simcere for autoimmune trispecific for $1.53bn.
Roche
Biopharmaceutical company - Diagnostics
Company Info
Recent News
Why Roche is 'really excited' about UCN2's obesity potential
Why Roche is 'really excited' about UCN2's obesity potential
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance
Roche bets $1B+ on DualityBio's ADC tech to tackle payload resistance
Roche-Hanmi, Akeso, a congressman's concerns—Fierce Pharma Asia
Roche-Hanmi, Akeso, a congressman's concerns—Fierce Pharma Asia
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Roche's Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
Roche's Genentech strikes $2.3bn deal for Hanmi obesity drug HM17321
Roche drops lupus TCE, retains autoimmune cell therapy interest
Roche drops its lupus T-cell engager program but retains broader autoimmune cell therapy ambitions following pipeline review.
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add M&A
Roche CEO Schinecker says the company's late-stage pipeline is "so full" he's not feeling pressure to pursue major M&A.
Roche KRAS drug succeeds in head-to-head lung cancer study
Roche KRAS drug succeeds in head-to-head lung cancer study (reported by BioPharma Dive)
Roche orchestrates phase 3 lung cancer win over Amgen and BMS
Roche orchestrates phase 3 lung cancer win over Amgen and BMS — Fierce Biotech coverage of biopharma industry developments.
Roche tops cancer reputation rankings as AstraZeneca climbs back
Roche tops cancer reputation rankings as AstraZeneca climbs back. (Fierce Pharma.)
With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs
With New Phase 3 Data, Roche Claims an Edge Over Amgen and BMS Lung Cancer Drugs — MedCity News coverage of biopharma industry developments.